Background: X-linked adrenal hypoplasia congenita is a rare cause of primary adrenal insufficiency (PAI) in children due to mutations in NR0B1/DAX1 (nuclear receptor subfamily 0, group B, member 1/dosage-sensitive sex reversal-adrenal hypoplasia congenita at the critical region of the X chromosome, gene 1). Another rare cause of PAI in children is autoimmune adrenal disease (AAD) which could be either isolated or as part of autoimmune polyglandular syndrome. Antibody to major auto-antigen, 21-hydroxylase, is highly specific for AAD. Methods: We report a now 19-month-old male with PAI due to NR0B1 gene mutation and positive adrenal antibodies. Initially, he presented at 15 days of life with isolated hypoaldosteronism which later unfolded into complete PAI. Data analysis was done via retrospective chart review. Results: Genetic analysis of the NR0B1 gene revealed a known hemizygous mutation in c.1069C>T; p.Gln357X. Simultaneously, he was noted to have positive 21-hydroxylase antibodies. Conclusion: According to our knowledge, this is the first case in the literature with NR0B1 mutation causing adrenal insufficiency with coexistent positive adrenal antibodies. In addition to his already compromised adrenal function due to NR0B1 mutation, he is now at risk for the development of associated autoimmune conditions requiring close follow-up.

Keywords:
Autoimmune adrenalitis, Adrenal insufficiency, Adrenal hypoplasia congenita, NR0B1 gene mutation, Autoimmune polyglandular syndrome
1.
Husebye E, Allolio B, Arlt W, Badenhoop K, Bensing S, Betterle C, et al: Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med 2014;275:104-115.
2.
Betterle C, Morlin L: Autoimmune Addison's disease. Endocr Dev 2011;20:161-172.
3.
Ten S, New M, Maclaren N: Clinical review 130: Addison's disease 2001. J Clin Endocrinol Metab 2001;86:2909-2922.
4.
Schuetz P, Christ-Crain M, Schild U, Süess E, Facompre M, Baty F, et al: Effect of a 14-day course of systemic corticosteroids on the hypothalamic-pituitary-adrenal-axis in patients with acute exacerbation of chronic obstructive pulmonary disease. BMC Pulm Med 2008;8:1.
5.
Ortega E, Rodriguez C, Strand LJ, Segre E: Effects of cloprednol and other corticosteroids on hypothalamic-pituitary-adrenal axis function. J Int Med Res 1976;4:326-337.
6.
Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA: Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000;355:542-545.
7.
Karamouzis I, Berardelli R, Marinazzo E, D'Angelo V, Zinna D, Minetto MA, et al: The acute effect of fludrocortisone on basal and hCRH-stimulated hypothalamic-pituitary-adrenal (HPA) axis in humans. Pituitary 2013;16:378-385.
8.
Sikl H: Addison's disease due to congenital hypoplasia of the adrenals in an infant aged 33 days. J Pathol Bacteriol 1948;60:323.
9.
Kelch RP, Virdis R, Rapaport R, Greig F, Levine L, New M: Congenital adrenal hypoplasia. Pediatr Adolesc Endocrinol 1984;13:156-161.
10.
Walker AP, Chelly J, Love DR, Brush YI, Récan D, Chaussain J-L, et al: A YAC contig in Xp21 containing the adrenal hypoplasia congenita and glycerol kinase deficiency genes. Hum Mol Genet 1992;1:579-585.
11.
Worley KC, Ellison KA, Zhang YH, Wang DF, Mason J, Roth EJ, et al: Yeast artificial chromosome cloning in the glycerol kinase and adrenal hypoplasia congenita region of Xp21. Genomics 1993;16:407-416.
12.
Zanaria E, Muscatelli F, Bardoni B, Strom TM, Guioli S, Guo W, et al: An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita. Nature 1994;372:635-641.
13.
Muscatelli F, Strom TM, Walker AP, Zanaria E, Recan D, Meindl A, et al: Mutations in the DAX-1 gene give rise to both X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism. Nature 1994;372:672-676.
14.
Morohashi K: The ontogenesis of the steroidogenic tissues. Genes Cells 1997;2:95-106.
15.
Keegan CE, Hammer GD: Recent insights into organogenesis of the adrenal cortex. Trends Endocrinol Metab 2002;13:200-208.
16.
McCabe E: Adrenal Hypoplasias and Aplasias. The Metabolic and Molecular Bases of Inherited Disease. New York McGraw-Hill, 2001, pp 4263-4274.
17.
Peter M, Viemann M, Partsch CJ, Sippell WG: Congenital adrenal hypoplasia: clinical spectrum, experience with hormonal diagnosis, and report on new point mutations of the DAX-1 gene. J Clin Endocrinol Metab 1998;83:2666-2674.
18.
Brook CG, Bambach M, Zachmann M, Prader A: Familial congenital adrenal hypoplasia. Helv Paediatr Acta 1973;28:277-282.
19.
Iyer AK, McCabe ER: Molecular mechanisms of DAX1 action. Mol Genet Metab 2004;83:60-73.
20.
Betterle C, Scalici C, Presotto F, Pedini B, Moro L, Rigon F, et al: The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocrinol 1988;117:467-475.
21.
Betterle C, Dal Pra C, Mantero F, Zanchetta R: Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 2002;23:327-364.
22.
Arlt W, Allolio B: Adrenal insufficiency. Lancet 2003;361:1881-1893.
23.
Falorni A, Laureti S, De Bellis A, Zanchetta R, Tiberti C, Arnaldi G, et al: Italian Addison network study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. J Clin Endocrinol Metab 2004;89:1598-1604.
24.
Mantovani G, De Menis E, Borretta G, Radetti G, Bondioni S, Spada A, et al: DAX1 and X-linked adrenal hypoplasia congenita: clinical and molecular analysis in five patients. Eur J Endocrinol 2006;154:685-689.
25.
Kletter GB, Gorski JL, Kelch RP: Congenital adrenal hypoplasia and isolated gonadotropin deficiency. Trends Endocrinol Metab 1991;2:123-128.
26.
Yanase T, Takayanagi R, Oba K, Nishi Y, Ohe K, Nawata H: New mutations of DAX-1 genes in two Japanese patients with X-linked congenital adrenal hypoplasia and hypogonadotropic hypogonadism. T J Clin Endocrinol Metab 1996;81:530-535.
27.
Kelly W, Joplin G, Pearson G: Gonadotrophin deficiency and adrenocortical insufficiency in children: a new syndrome. BMJ 1977;2:98.
28.
Takahashi T, Shoji Y, Shoji Y, Haraguchi N, Takahashi I, Takada G: Active hypothalamic-pituitary-gonadal axis in an infant with X-linked adrenal hypoplasia congenita. J Pediatr 1997;130:485-488.
29.
Reutens AT, Achermann JC, Ito M, Ito M, Gu WX, Habiby RL, et al: Clinical and functional effects of mutations in the DAX-1 gene in patients with adrenal hypoplasia congenita. J Clin Endocrinol Metab 1999;84:504-511.
30.
Takahashi I, Takahashi T, Shoji Y, Takada G: Prolonged activation of the hypothalamus-pituitary-gonadal axis in a child with X-linked adrenal hypoplasia congenita. Clin Endocrinol (Oxf) 2000;53:127-129.
31.
Landau Z, Hanukoglu A, Sack J, Goldstein N, Weintrob N, Eliakim A, et al: Clinical and genetic heterogeneity of congenital adrenal hypoplasia due to NR0B1 gene mutations. Clin Endocrinol (Oxf) 2010;72:448-454.
32.
Binder G, Wollmann H, Schwarze CP, Strom TM, Peter M, Ranke MB: X-linked congenital adrenal hypoplasia: new mutations and long-term follow-up in three patients. Clin Endocrinol (Oxf) 2000;53:249-255.
33.
Betterle C, Volpato M, Rees Smith B, Furmaniak J, Chen S, Zanchetta R, et al: II. Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: markers of high progression to clinical Addison's disease. J Clin Endocrinol Metab 1997;82:939-942.
34.
Falorni A, Chen S, Zanchetta R, Yu L, Tiberti C, Bacosi ML, et al: Measuring adrenal autoantibody response: interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies. Clin Immunol 2011;140:291-299.
35.
Betterle C, Lazzarotto F, Presotto F: Autoimmune polyglandular syndrome type 2: the tip of an iceberg? Clin Exp Immunol 2004;137:225-233.
36.
Sarathi V, Shah NS: Triple-A syndrome. Adv Exp Med Biol 2010;685:1-8.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.